New studies show APTA-1 has positive affect on key factors related to blood coagulation

Aptahem announce that the results from studies carried out over recent months’, in a series of targeted animal studies, show that its lead compound APTA-1 demonstrates a positive effect on a number of key features related to the coagulation process, some of them not present in today’s medicines. The studies were carried out at laboratories in Europe, North America and Asia.

One consistent observation in all the studies is that the anticoagulant effect of APTA-1, such as the reduction in size of thrombus, occur at non-toxic doses. This differentiates it from today’s anticoagulation drugs, and Aptahem is continuing to characterize APTA-1’s effects on cellular functions to determine its potential as a drug.

Michael Lindstam, CEO of Aptahem, explained that these results highlight the future promise for APTA-1 as a drug candidate with the potential to offer patients a better safety profile than current medications.

For further information:
Michael Lindstam, CEO Aptahem AB
Tel: + 46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem is developing drug candidates for the treatment and prevention of diseases caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke, and heart failure. Thrombosis, also called clot, is the medical term for an increased and unhealthy coagulation of blood cells that cause more than 30 percent of all deaths worldwide. Thrombosis occurs either through genetic inheritance or by thrombosis occurs in conjunction with surgery, trauma, due to medication or by the victim suffering from a disease such as cancer. The company holds patents for Europe, China, the United States and Canada and the patent application in India.

Forward-looking statements
This communication contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as well as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.